QS MedTech Unveils 'X Needle-Free Drug Delivery Platform,' Reshaping the Future of Medical Administration

On January 17, 2025, the inaugural “Technology × Love” Kuaishu'er Needle-Free Drug Delivery Technology Innovation Summit was grandly held at the National Information Technology Application Innovation Park in the Beijing Economic-Technological Development Area (BDA). Leaders from relevant departments, including the Beijing Municipal Science & Technology Commission, the Health Commission, the Drug Administration, and the Administrative Committee of the Beijing BDA, along with renowned medical experts in the field of endocrinology, attended the event. Dozens of global healthcare companies, such as WuXi Biologics, Fosun Pharma, GeneScience Pharmaceuticals, JD Health, Medtronic, and Sinocare, gathered to witness Kuaishu'er Medical’s significant breakthroughs in needle-free injection technology, marking a critical step forward in China’s independent innovation in medical technology.

The drawbacks of traditional needle injections are significant. Patients commonly exhibit needle phobia, leading to poor treatment adherence and limiting market penetration for pharmaceutical products. Furthermore, medical sharps waste generated by injections poses substantial disposal challenges. Such waste not only carries a high risk of needlestick injuries to healthcare workers but also requires specialized collection, transportation, and harmless disposal processes. The considerable human, material, and financial resources involved impose a heavy economic burden on healthcare institutions and society at large. Additionally, issues associated with traditional injections, such as pain and infection risks, adversely affect patient experience and constrain the development of pharmaceutical R&D enterprises. Zhang Yong, Head of the Growth Hormone Device Business Division at GenSci Pharmaceutical, stated, “GenSci has consistently adhered to the concept of integrating pharmaceuticals with medical devices, seeking to improve the injection experience. Our goal is to provide better services and enhance the experience for children during their growth and development. Improving patient experience is the direction pursued by our device division, which is why we chose to partner with Kuaishu'er.”

Since 2005, Kuaishu'er Medical has been dedicated to the research and development of needle-free delivery technology. By applying principles of fluid dynamics, this technology precisely injects medication into the subcutaneous tissue as an ultra-fine liquid stream, reaching the predetermined depth within 0.3 seconds. This innovation significantly enhances patient medication experience and drug absorption efficiency, while also eliminating the generation of medical sharps waste, substantially reducing disposal costs, and enabling more rational utilization of healthcare resources. A global search revealed that among a total of 63 SCI-indexed publications related to needle-free injection, 56 were based on Kuaishu'er's technology. Backed by robust clinical evidence and collaborative efforts from top Chinese universities and relevant government departments, Kuaishu'er has achieved a series of major breakthroughs over 20 years of dedicated research, leveraging fluid dynamics and human subcutaneous simulation technologies. In 2014, China’s first independently developed QS-M needle-free injector, with proprietary intellectual property rights, received market approval, filling a domestic gap. Subsequently, the QS-P model and the child-specific QS-P Vibrant Color Edition were launched, serving hundreds of thousands of users. These advancements mark a comprehensive upgrade from injection devices to integrated injection systems, demonstrating the strength of China’s independent innovation in medical technology.

“Kuaishu'er is accelerating the joint development of combination drug-device products with major pharmaceutical companies both in China and abroad, speeding up the comprehensive localization and internationalization of needle-free products. This fully demonstrates the company’s strong momentum in innovation and its broad prospects for commercial application,” said Guo Meng, Deputy Director of the Biotechnology and Big Health Industry Bureau of the Economic-Technological Development Area, praising Kuaishu'er's innovative capabilities.

At this summit, Kuaishu'er unveiled its globally advanced “X Needle-Free Drug Delivery Technology Platform,” which integrates multidisciplinary technologies. This platform incorporates Kuaishu'er’s latest needle-free delivery innovations to precisely match drug administration parameters with the specific characteristics of different drugs, providing pharmaceutical R&D enterprises with targeted, mass-producible drug delivery solutions. It enables more efficient and safe drug delivery, meeting requirements for subcutaneous, intradermal, and intramuscular injections. This not only expands the application scope of needle-free injection technology but also removes technical barriers related to injection methods in new drug development, thereby facilitating the entry of more innovative drugs into clinical trials and the market, and helping propel China’s pharmaceutical R&D industry to new heights.

At the summit, Kuaishu'er Medical leveraged the technological advantages of its “X Needle-Free Drug Delivery Technology Platform” to launch three new products exclusively on the JD.com platform, showcasing its innovation prowess. The special “Lilac Purple” edition addresses women’s needs, reflecting humanistic care in every detail. The QLINK system and accessories, developed based on AI, big data, and cloud storage concepts, enable intelligent upgrades for chronic disease injection diagnosis and treatment, thereby improving the quality and efficiency of medical services. The QS-X needle-free injection pen, a device-drug combination product, made its global debut through a partnership with JD.com. As a world-first technology that loads an entire cartridge of liquid medication into the pen for multiple doses, it is compatible with drugs packaged in the widely used global standard “3ml cartridge” format, resolving a long-standing industry challenge. During its development, 23 domestic and international patents were filed, setting a benchmark for the growth of China’s high-end medical device industry.

“The global medical device industry is currently undergoing unprecedented change, with technological innovation serving as the core driver of its development,” stated Yu Langbai, Deputy Director of the Production Supervision Division of the Beijing Municipal Medical Products Administration. “As a sunrise industry, the continuous emergence of technological innovations in the medical device sector has injected strong momentum into its growth, ushering in a rare and promising outlook for future development.”

At the summit, Kuaishu'er Medical’s innovative achievements and broad prospects in needle-free delivery technology attracted significant attention from numerous enterprises. Notably, three industry leaders—WuXi Biologics, GeneScience Pharmaceuticals, and Sinocare Inc.—officially signed strategic cooperation agreements with Kuaishu'er Medical. This collaboration will focus on in-depth exploration of needle-free injection technology in areas such as new drug development and product optimization. Leveraging its leading technologies in biopharmaceutical R&D, WuXi Biologics’ partnership with Kuaishu'er is expected to promote the expanded application of needle-free injection in the biologics sector. GeneScience Pharmaceuticals, which specializes in fields such as growth hormones, will further enhance patient experience by utilizing Kuaishu'er’s “X Needle-Free Drug Delivery Technology Platform.” With extensive experience in chronic disease management, including blood glucose monitoring, Sinocare Inc. will collaborate with Kuaishu'er to improve end-to-end services for chronic disease treatment. These partnerships will fully leverage the respective strengths of all parties, achieve mutual benefits, and jointly promote the coordinated development of needle-free injection technology and pharmaceutical R&D.

“The QS-X needle-free injector released today is a global premiere and the only needle-free injection system capable of using cartridge vials as its drug packaging material. I am quite excited, as a researcher, to see such cutting-edge technology emerging in China; I find it truly remarkable.” Dr. Chen Quanmin from WuXi Biologics expressed strong confidence in future collaboration with Kuaishu'er, stating, “We are eager to partner with innovative enterprises like Kuaishu'er to rapidly translate the latest technologies and products into benefits for patients.”

Professor Ji Linong from the Department of Endocrinology at Peking University People’s Hospital also shared insights regarding the costs associated with needle-free injection. He pointed out that drug production benefits significantly from economies of scale, while needle-free injection holds substantial potential in terms of administration cost accounting. If further optimized, it could play a key role in reducing the overall production costs of pharmaceuticals. Compared with existing packaging materials and injection methods, this approach can alleviate the financial burden on the government, manufacturers, and patients.

Zhang Yuxin, founder of Kuaishu'er Medical, pointed out that this new product launch is merely a significant milestone in the company’s development. In the future, Kuaishu'er Medical will leverage the advantages of its “X Needle-Free Drug Delivery Technology Platform” to continuously increase R&D investment and introduce more innovative products that align with market demands. Meanwhile, the company will actively collaborate with more partners to respond to the national strategy of building a science and technology powerhouse, vigorously promoting technological innovation in the medical sector.

“The successful convening of today’s Needle-Free Drug Delivery Technology Summit is not only an important milestone in the rapid development of Kuaishu'er, but also a concentrated demonstration of the innovation achievements and new quality productive forces in the medical device sector within the Economic-Technological Development Area. I believe that this summit will further promote the development and promotion of high-quality innovative products represented by needle-free drug delivery technology, thereby making greater contributions to the national health cause,” said Guo Meng, Deputy Director of the Biotechnology and Big Health Industry Bureau of the Economic-Technological Development Area.

Through continuous innovation and upgrades in needle-free delivery technology, Beijing Kuaishu'er Medical Technology Co., Ltd. not only assists domestic pharmaceutical R&D enterprises in expanding into international markets. Leveraging its significant technological advantages, the company enhances the global competitiveness of drug products incorporating this technology, facilitating the acquisition of international cooperation orders and market access approvals. This strongly promotes the internationalization of China’s pharmaceutical enterprises and boosts the global influence of China’s pharmaceutical industry. Furthermore, the company aims to provide more high-quality technologies and products for China’s healthcare sector, giving back to government support and helping to improve the health levels of the entire population, thereby contributing to China’s goal of becoming a scientific and technological powerhouse in the global tech competition.